Best Options Strategy for BBIO
Looking for the best options strategy for BridgeBio Pharma, Inc. (BBIO)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live BBIO option chain right now, and a simple map from your view on BBIO to the strategy that fits it. Model any of them in the calculator before you trade.
About BBIO
BridgeBio Pharma, Inc. (BBIO) is a major company in Biotechnology. Options traders on BBIO tend to watch , since these can drive large moves in the share price.
About BridgeBio Pharma, Inc.
BridgeBio Pharma develops and commercializes medicines targeting genetic diseases, with a pipeline spanning small molecule drugs, gene therapies, and other modalities. The company's marketed product Attruby treats a form of heart amyloidosis by stabilizing the transthyretin protein, while Nulibry addresses molybdenum cofactor deficiency through synthetic enzyme replacement. Its clinical-stage candidates include infigratinib for growth disorders in children, encaleret for calcium regulation disorders, and several investigational therapies for muscular dystrophy and neurological conditions like Canavan disease. BridgeBio also pursues development programs across mendelian disorders and oncology.
The company generates revenue from product sales and leverages partnerships with major pharmaceutical and research organizations, including Novartis, Bayer, and Stanford University, to fund development efforts. As a biopharmaceutical firm founded in 2015 and based in Palo Alto, California, BridgeBio operates in the rare genetic disease space, where patient populations are small but treatment options limited and unmet medical needs substantial. The company's financial model depends on…
Today's top-scoring strategy for BBIO
Our engine ranks defined-risk strategies on the live BBIO chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $60 | $0.05 |
| Sell | 1× | PUT | $75 | $1.85 |
| Sell | 1× | CALL | $75 | $3.23 |
| Buy | 1× | CALL | $90 | $0.25 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Live scan from 2026-07-02 · quotes delayed ~15 minutes
Implied volatility
BBIO is currently trading with elevated implied volatility, so its options carry richer premiums. On the options we scanned that was around 44% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on BBIO currently price in about 44% implied volatility, versus roughly 33% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$6.67 (±9%) in BBIO by 2026-07-17 — a range of roughly $69.58 to $82.92. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, puts and calls on BBIO carry a fairly symmetric implied volatility — no strong directional fear is priced in either way.
Liquidity and tradeability
BBIO options are thinly traded, with wide bid-ask spreads around 24.8% near the money that eat into any edge — favour simple single-leg or tight defined-risk trades, and always use limit orders.
Earnings & IV crush
BBIO's next earnings report is due around August 4, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $15.1B
- Beta (vs market)
- 0.97
- 52-week range
- $42.09–$84.94 (80% up the range)
- Short interest
- 14.5% of float · 9.1 days to cover
With 14.5% of BBIO's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
Other strong setups for BBIO
If your view on BBIO differs, these also scored well in the latest scan:
How to choose an options strategy for BBIO
Start with your outlook on BBIO, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while BBIO stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open BBIO in the free calculator →
Frequently asked questions
What is the best options strategy for BBIO?
It depends on your outlook. Bullish traders often use a long call or bull call spread on BBIO; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are BBIO options liquid enough to trade?
BridgeBio Pharma, Inc. (BBIO) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade BBIO options?
Buying a single BBIO call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade BBIO or any security. Do your own research.
What does BridgeBio Pharma, Inc. do?
BridgeBio Pharma, Inc. (BBIO) operates in the Biotechnology industry. The "About BridgeBio Pharma, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does BridgeBio Pharma, Inc. pay a dividend?
BridgeBio Pharma, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does BridgeBio Pharma, Inc. next report earnings?
BridgeBio Pharma, Inc.'s next earnings are expected around August 4, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to BBIO
Comparing BBIO with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 3160 Porter Drive, Suite 250, Palo Alto, CA, 94304, United States
- Industry
- Biotechnology
- Employees
- 834
- CEO
- Dr. Neil Kumar Ph.D.
- Phone
- 650 391 9740
- Website
- bridgebio.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.